MetaCap

Incannex Healthcare Inc. (IXHL)

NASDAQ: IXHLHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.86+0.12 (+6.90%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IXHL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$23.34M
EPS (TTM)
-$1.25
52-week range
1.61 – 14.91
Day range
1.69 – 1.99
Volume / Avg
219.82K / 91.61K
Beta
—

52-week range

$1.61$14.91

IXHL stock today

Incannex Healthcare (IXHL) closed at $1.86 on Nov 20, up 6.90% (+$0.12), versus the S&P 500's 3.70% decline. Volume was 2.4x the average at 219.82K shares, a sign of unusually heavy trading. Shares are 87.5% below their 52-week high of $14.91, set on Dec 4, 2025 and 15.5% above the 52-week low of $1.61, near the bottom of the past year's range.

IXHL is down 82.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 80.3%. Incannex Healthcare has posted a net loss over the last twelve months (EPS of -$1.25), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Incannex Healthcare

Company profile

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Joel Bradley Latham
Headquarters
Melbourne, VIC
Employees
12

Financial highlights

Full financials

In fiscal 2026, Incannex Healthcare generated $0 in revenue, down 100.0% from fiscal 2025, the first decline in the 7 years shown. Incannex Healthcare reported a net loss of $19.3 million, compared with a loss of $46.9 million a year earlier. Diluted earnings per share came in at -$1.66.

Incannex Healthcare annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue$0$86.00K$12.00K——
Growth-100.00%+616.67%———
Net income$-19.30M$-46.88M$-18.46M$-48.81M$-14.90M
EPS (diluted)$-1.66$-40.82$-1.15$-3.32$-1.25

Analyst forecast

Forecast

Consensus (1 analysts)

strong_buy

Avg. price target

$18.68+904.30%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $18.02High $19.33

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.15 vs $-0.66
Surprise
+77.27%

Incannex Healthcare peers

Health Care sector
IXHL peer companies
CompanyPrice% ChgMarket capCompare
ABVCABVC BioPharma Inc.0.8663-1.56%$23.37Mvs IXHL
RMTIRockwell Medical Inc.5.82-7.03%$23.12Mvs IXHL
SCYXSCYNEXIS Inc.2.38-8.64%$23.69Mvs IXHL
IMMPImmutep Limited ADR3.11-9.06%$22.92Mvs IXHL
LITSLite Strategy Inc.0.8026-4.03%$23.99Mvs IXHL
CRVOCervoMed Inc.1.46+9.77%$22.09Mvs IXHL
AARDAardvark Therapeutics Inc.0.9226-7.74%$20.20Mvs IXHL
RNAZTransCode Therapeutics Inc.1.16-10.77%$20.07Mvs IXHL

Indexes, lists and sector

Incannex Healthcare stock FAQ

What is Incannex Healthcare's stock price today?

IXHL last traded at $1.86 as of Nov 20, 4:00 PM EST, up 6.90% on the day. Prices are delayed at least 15 minutes.

Does Incannex Healthcare pay a dividend?

No. Incannex Healthcare does not currently pay a regular cash dividend.

Who is Incannex Healthcare's CEO?

Mr. Joel Bradley Latham is the chief executive officer of Incannex Healthcare Inc., which has about 12 employees.

Has IXHL ever split its stock?

Yes. The most recent IXHL stock split was a 1-for-30 split on Feb 27, 2026.

What is the IXHL 52-week high?

The 52-week high for IXHL is $14.91 and the 52-week low is $1.61. The stock is currently 87.5% below its high.

Compare IXHL